Welcome to our dedicated page for MAIA Biotechnology news (Ticker: MAIA), a resource for investors and traders seeking the latest updates and insights on MAIA Biotechnology stock.
MAIA Biotechnology, Inc. (NYSE American: MAIA) is a clinical-stage biopharmaceutical company whose news flow is closely tied to the development of ateganosine (THIO), a first-in-class telomere-targeting therapy for advanced non-small cell lung cancer (NSCLC). News about MAIA often centers on clinical milestones, regulatory designations, and financing activities that support its oncology programs.
Investors and observers following MAIA’s news can expect regular updates on its Phase 2 THIO-101 and Phase 3 THIO-104 trials. These items include announcements of first patient dosing, expansion into new countries, enrollment progress, and presentations of trial-in-progress posters at major conferences such as the Society for Immunotherapy of Cancer (SITC), the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, and the European Society for Medical Oncology (ESMO) Congress.
MAIA’s press releases, many of which are furnished via Form 8-K filings, also highlight regulatory developments such as the U.S. FDA Fast Track designation for ateganosine in NSCLC and Orphan Drug Designations in additional tumor types. Another recurring theme in the company’s news is insider activity: open-market share purchases by the CEO and directors, and participation by board members in private placement financings, which the company frames as signals of confidence in the ateganosine platform.
On this news page, readers can review MAIA’s announcements related to clinical data signals, trial design details, international site activations, and capital raises that fund key study steps. For those tracking the progress of telomere-targeting approaches in oncology and the later-line NSCLC treatment landscape, MAIA’s news provides an ongoing record of how its investigational therapy is advancing through mid- to late-stage clinical development.
MAIA Biotechnology, Inc. reported financial results for Q3 2022, highlighting a net loss of approximately
MAIA Biotechnology, Inc. (NYSE American: MAIA) announced its participation in the ThinkEquity Conference on October 26 at 3:00 pm ET. The management team will present and host investor meetings during the event. A webcast of the presentation will be accessible via the Company's website, with a replay available for 30 days post-event. MAIA focuses on developing first-in-class oncology drugs, particularly THIO for NSCLC.
MAIA Biotechnology, Inc. (NYSE American: MAIA) announced it will present study results of the anticancer agent 6-thio-dG (THIO) for hepatocellular carcinoma (HCC) at the EORTC-NCI-AACR Symposium, occurring in Barcelona, Spain from Oct. 26-28, 2022. The data indicates THIO's high anticancer activity and improved tumor response when used sequentially with cemiplimab in HCC models. The U.S. FDA granted THIO Orphan Drug Designation for HCC earlier in 2022, a disease projected to exceed 1 million global cases by 2025.
Presentation is scheduled for Oct. 26 at 12:00pm CEST.
MAIA Biotechnology, Inc. (NYSE American: MAIA) will participate in the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14. The management team is set to present on September 12 at 7:00 am ET and will hold investor meetings until September 14. A webcast of the presentation will be available on the Company's website, with a replay accessible for 30 days post-event. MAIA focuses on developing first-in-class oncology drugs aimed at improving cancer treatment outcomes.
MAIA Biotechnology, Inc. (NYSE American: MAIA) announced the upcoming presentation of its ongoing THIO-101 trial design at the ESMO Congress 2022 in Paris from September 9-13. The trial evaluates THIO, a telomere-targeting agent, in combination with cemiplimab for advanced non-small cell lung cancer (NSCLC). The first patient was enrolled in July 2022 in Australia. The presentation is scheduled for September 12, under the title: 'A Phase 2, Multicenter, Open-Label, Dose-Finding Study Evaluating THIO Sequenced with Cemiplimab in Patients with Advanced NSCLC'.
MAIA Biotechnology, Inc. has been selected to present its innovative THIO platform at the XIV International Round Table on Nucleosides in Stockholm, Sweden, from August 28 to 31, 2022. This platform showcases the modified nucleoside 6-thio-2’-deoxyguanosine (6-thio-dG) as a promising anticancer agent. The presentation will highlight how THIO may enhance immune responses and overcome therapy resistance. MAIA aims to develop THIO for non-small cell lung cancer patients resistant to existing checkpoint inhibitors.
MAIA Biotechnology, Inc. (NYSE American: MAIA) reported its second-quarter 2022 financial results, highlighting significant advancements in its clinical development of THIO, an immunotherapy for cancer. The company has initiated a Phase 2 trial for Non-Small Cell Lung Cancer (NSCLC) and received orphan drug designations from the FDA for two additional indications: Small Cell Lung Cancer (SCLC) and Hepatocellular Carcinoma (HCC). MAIA completed its IPO on August 1, raising $11.5 million, and reported a net loss of approximately $3.3 million for the quarter.
MAIA Biotechnology has received Orphan Drug Designation for THIO, its telomere-targeting agent, from the FDA. This designation applies to THIO's potential in treating small-cell lung cancer (SCLC) and builds on its previous designation for hepatocellular carcinoma (HCC). The company sees THIO as having a significant multi-billion-dollar opportunity in oncology. SCLC patients face a grim prognosis, with only 6% surviving five years post-diagnosis, highlighting the need for effective treatments.
MAIA Biotechnology, Inc. has successfully closed its initial public offering, issuing 2,000,000 shares at a price of $5.00 per share, resulting in gross proceeds of $10,000,000. The shares began trading on the NYSE American on July 28, 2022, under the ticker symbol MAIA. The proceeds will fund the Phase 2 trials of its product candidate THIO and support further development of telomere-targeting compounds. Underwriters are granted a 45-day option to purchase an additional 300,000 shares to cover overallotments.
MAIA Biotechnology, Inc. has priced its initial public offering of 2,000,000 shares at $5.00 each, expecting gross proceeds of $10,000,000. The shares will trade under the ticker symbol MAIA starting July 28, 2022, with the offering closing on August 1, 2022, pending customary conditions. The proceeds will fund Phase 2 trials for the product candidate THIO, pre-clinical development of new compounds, and general corporate purposes. ThinkEquity is managing the offering.
FAQ
What is the current stock price of MAIA Biotechnology (MAIA)?
What is the market cap of MAIA Biotechnology (MAIA)?
